Illumina's partners say they believe the company will continue to improve the speed and continue to lower the price.
San Diego-based Illumina, Inc., has launched a "production scale” sequencer that it claims can process human genomes in half a day for $200.
Illumina CEO Francis deSouza says the company's new NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus) have the power to more-accurately sequence more than 20,000 genomes each year – which is twice the capacity of earlier sequencers -- and will "push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing.”
"Today, we are forging a new path forward to advance more breakthroughs in cancer and genetic disease treatments, precision therapies, and pandemic preparedness," deSouza says.
"Innovations like NovaSeq X are at the heart of how we will transform patient lives, and this groundbreaking technology will empower researchers, scientists, and clinicians in the fight to diagnose, treat – and eventually cure – disease while making genomics more sustainable and accessible to millions more people around the world."
Along with speed and cost, Illumina – which controls about 80% of the global genome sequencing market -- says the NovaSeq X also reduces packaging waste and weight by 90% and cuts plastic use in half when compared to NovaSeq 6000. Ambient-temperature shipping of reagents will also eliminate the need for nearly 500 tons of dry ice each year and waste for customers. Illumina will begin to distribute the NovaSeq™ X Series machines in 2023
Illumina's partners say they believe the company will continue to improve the speed and continue to lower the price.
"We're very excited to be a launching partner for NovaSeq X Series. Macrogen always strives to become the champion of personal whole genome sequencing," said Professor Jeongsun Seo, Chairman of Macrogen, a Korean international sequencing services provider that uses Illumina technology.
"I strongly believe NovaSeq X Series will accelerate our path towards the $100 genome. This will enable us to deliver a genetic blueprint to everyone in the world to unlock individual potential and increase life quality."
“Today, we are forging a new path forward to advance more breakthroughs in cancer and genetic disease treatments, precision therapies, and pandemic preparedness.”
Francis deSouza, CEO, Illumina, Inc.
John Commins is the news editor for HealthLeaders.
KEY TAKEAWAYS
Along with speed and cost, Illumina – which controls about 80% of the global genome sequencing market -- says the NovaSeq X also reduces packaging waste and weight by 90% and cuts plastic use in half when compared to NovaSeq 6000.
Ambient-temperature shipping of reagents will also eliminate the need for nearly 500 tons of dry ice each year and waste for customers. Illumina will begin to distribute the NovaSeq™ X Series machines in 2023